InvestorsHub Logo
Followers 21
Posts 2539
Boards Moderated 0
Alias Born 12/07/2013

Re: None

Saturday, 10/22/2022 9:15:11 AM

Saturday, October 22, 2022 9:15:11 AM

Post# of 425927
SGLT's will totally eclipse vascepa. SGLT'S are now indicated for the treatment of DM2 and prevention of CAD and CRF. The large pharmaceutical firms are rewriting the narrative connecting the dots between DM2, CRF and CAD and their common physiology positioning SGLT's for early intervention and prevention - VAscepa will remain a footnote on the bottom of the page in a font that is barely readable .

This ole investor makes it on time
Leaves Wall Street Station
'Bout a quarter to nine
Hits SHortnin Junction at seventeen: two
At a quarter to ten
You know he's shortnin again
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News